Expression of Vascular Endothelial Growth Factor (VEGF) in Epithelial Ovarian Neoplasms: Correlation with Clinicopathology and Patient Survival, and Analysis of Serum VEGF Levels

Overview

Journal Br J Cancer

Specialty Oncology

Date 1997 Jan 1

PMID 9365173

Citations 88

Authors

S Yamamoto

I Konishi

M Mandai

H Kuroda

T Komatsu

K Nanbu

H Sakahara

T Mori

Affiliations

Soon will be listed here.

Abstract

Vascular endothelial growth factor (VEGF) is known to be produced by various solid tumours and is thought to be involved in microvascular permeability and/or angiogenesis. To examine the relationship between VEGF expression in ovarian neoplasms and clinicopathological factors or patient survival, expression of VEGF was analysed immunohistochemically in 110 epithelial ovarian tumours. In addition, VEGF levels in the tumour fluid (17 patients), ascites (12 patients) and sera (38 patients) were determined using enzyme immunoassay. Positive immunostaining for VEGF was observed in 97% (68 out of 70) of ovarian carcinomas, which was significantly higher than that of tumours of low malignant potential (LMP) (13 out of 25; 52%) and benign cystadenomas (5 out of 15; 33%) (P < 0.01). In ovarian carcinomas, strong VEGF immunostaining was also observed more frequently in tumours of clear cell type (P < 0.05) in the advanced stage of disease (P < 0.05) and with positive peritoneal cytology (P < 0.01). Patients with strong VEGF staining had poorer survival rates than those with weak or no immunostaining for VEGF (P < 0.01). These findings suggest that strong VEGF expression plays an important role in the tumour progression of ovarian carcinoma. The enzyme immunoassay revealed higher serum VEGF levels in carcinoma patients than those in patients with LMP or benign tumours (P < 0.01). Serum VEGF levels decreased after the successful removal of tumours in ovarian cancer patients and, in one patient, the serum VEGF level was re-elevated during relapse. Therefore, serum VEGF could be used as a marker for monitoring the clinical course of ovarian cancer patients.

Citing Articles

Effect of bevacizumab in combination with chemotherapy for ovarian cancer on wound healing in patients: A meta-analysis.

Xue Y, Zhao F Int Wound J. 2023; 21(4):e14531.

PMID: 38151891 PMC: 10961034. DOI: 10.1111/iwj.14531.

Immune checkpoint inhibitors in ovarian cancer: where do we go from here?.

Yoon W, DeFazio A, Kasherman L Cancer Drug Resist. 2023; 6(2):358-377.

PMID: 37457131 PMC: 10344730. DOI: 10.20517/cdr.2023.13.

Predicting Prognosis and Platinum Resistance in Ovarian Cancer: Role of Immunohistochemistry Biomarkers.

Atallah G, Kampan N, Chew K, Mokhtar N, Md Zin R, Shafiee M Int J Mol Sci. 2023; 24(3).

PMID: 36768291 PMC: 9916805. DOI: 10.3390/ijms24031973.

Squalamines in Blockade of Tumor-Associated Angiogenesis and Cancer Progression.

Sterling Jr C, Marquez-Garban D, Vadgama J, Pietras R Cancers (Basel). 2022; 14(20).

PMID: 36291938 PMC: 9601113. DOI: 10.3390/cancers14205154.

Differential Expression of HIF1A, EPAS1, and VEGF Genes in Benign and Malignant Ovarian Neoplasia.

Englert-Golon M, Toklowicz M, Zbikowska A, Sajdak S, Kotwicka M, Andrusiewicz M Cancers (Basel). 2022; 14(19).

PMID: 36230822 PMC: 9563807. DOI: 10.3390/cancers14194899.

References

Plate K, Breier G, Weich H, Risau W . Vascular endothelial growth factor is a potential tumour angiogenesis factor in human gliomas in vivo. Nature. 1992; 359(6398):845-8. DOI: 10.1038/359845a0. View

Connolly D, Olander J, Heuvelman D, Nelson R, Monsell R, Siegel N . Human vascular permeability factor. Isolation from U937 cells. J Biol Chem. 1989; 264(33):20017-24. View

Yeo K, Wang H, Nagy J, Sioussat T, Ledbetter S, Hoogewerf A . Vascular permeability factor (vascular endothelial growth factor) in guinea pig and human tumor and inflammatory effusions. Cancer Res. 1993; 53(12):2912-8. View

Brown L, Berse B, Jackman R, Tognazzi K, Manseau E, Senger D . Expression of vascular permeability factor (vascular endothelial growth factor) and its receptors in adenocarcinomas of the gastrointestinal tract. Cancer Res. 1993; 53(19):4727-35. View

Brown L, Berse B, Jackman R, Tognazzi K, Manseau E, Dvorak H . Increased expression of vascular permeability factor (vascular endothelial growth factor) and its receptors in kidney and bladder carcinomas. Am J Pathol. 1993; 143(5):1255-62. PMC: 1887185. View

Olson T, Mohanraj D, Carson L, Ramakrishnan S . Vascular permeability factor gene expression in normal and neoplastic human ovaries. Cancer Res. 1994; 54(1):276-80. View

Senger D, Van de Water L, Brown L, Nagy J, Yeo K, Yeo T . Vascular permeability factor (VPF, VEGF) in tumor biology. Cancer Metastasis Rev. 1993; 12(3-4):303-24. DOI: 10.1007/BF00665960. View

Neufeld G, Tessler S, Cohen T, Levi B . Vascular endothelial growth factor and its receptors. Prog Growth Factor Res. 1994; 5(1):89-97. DOI: 10.1016/0955-2235(94)90019-1. View

Takahashi A, Sasaki H, Kim S, Tobisu K, Kakizoe T, Tsukamoto T . Markedly increased amounts of messenger RNAs for vascular endothelial growth factor and placenta growth factor in renal cell carcinoma associated with angiogenesis. Cancer Res. 1994; 54(15):4233-7. View

10.

Nagy J, Masse E, Herzberg K, Meyers M, Yeo K, Yeo T . Pathogenesis of ascites tumor growth: vascular permeability factor, vascular hyperpermeability, and ascites fluid accumulation. Cancer Res. 1995; 55(2):360-8. View

11.

Brown L, Berse B, Jackman R, Tognazzi K, Guidi A, Dvorak H . Expression of vascular permeability factor (vascular endothelial growth factor) and its receptors in breast cancer. Hum Pathol. 1995; 26(1):86-91. DOI: 10.1016/0046-8177(95)90119-1. View

12.

Kamat B, Brown L, Manseau E, Senger D, Dvorak H . Expression of vascular permeability factor/vascular endothelial growth factor by human granulosa and theca lutein cells. Role in corpus luteum development. Am J Pathol. 1995; 146(1):157-65. PMC: 1870764. View

13.

Samoto K, Ikezaki K, Ono M, Shono T, Kohno K, Kuwano M . Expression of vascular endothelial growth factor and its possible relation with neovascularization in human brain tumors. Cancer Res. 1995; 55(5):1189-93. View

14.

Boocock C, Charnock-Jones D, Sharkey A, McLaren J, Barker P, Wright K . Expression of vascular endothelial growth factor and its receptors flt and KDR in ovarian carcinoma. J Natl Cancer Inst. 1995; 87(7):506-16. DOI: 10.1093/jnci/87.7.506. View

15.

Sharkey A, Charnock-Jones D, Smith S . Localization and quantification of vascular endothelial growth factor messenger ribonucleic acid in human myometrium and leiomyomata. J Clin Endocrinol Metab. 1995; 80(6):1853-8. DOI: 10.1210/jcem.80.6.7775632. View

16.

Neulen J, Yan Z, Raczek S, Weindel K, Keck C, Weich H . Human chorionic gonadotropin-dependent expression of vascular endothelial growth factor/vascular permeability factor in human granulosa cells: importance in ovarian hyperstimulation syndrome. J Clin Endocrinol Metab. 1995; 80(6):1967-71. DOI: 10.1210/jcem.80.6.7775647. View

17.

Gordon J, Mesiano S, Zaloudek C, Jaffe R . Vascular endothelial growth factor localization in human ovary and fallopian tubes: possible role in reproductive function and ovarian cyst formation. J Clin Endocrinol Metab. 1996; 81(1):353-9. DOI: 10.1210/jcem.81.1.8550777. View

18.

Mattern J, Koomagi R, Volm M . Association of vascular endothelial growth factor expression with intratumoral microvessel density and tumour cell proliferation in human epidermoid lung carcinoma. Br J Cancer. 1996; 73(7):931-4. PMC: 2074250. DOI: 10.1038/bjc.1996.166. View

19.

Takano S, Yoshii Y, Kondo S, Suzuki H, Maruno T, Shirai S . Concentration of vascular endothelial growth factor in the serum and tumor tissue of brain tumor patients. Cancer Res. 1996; 56(9):2185-90. View

20.

Faix J, Niloff J, Tognazzi K, Manseau E, Dvorak H, Brown L . Strong expression of vascular permeability factor (vascular endothelial growth factor) and its receptors in ovarian borderline and malignant neoplasms. Lab Invest. 1996; 74(6):1105-15. View